secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001493152-24-030372
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q2 2024 revenue up 5.4% to $1.74M; net loss widens; positive CGuard trial data
--------------------------------------------------------------------------------

- Q2 2024 revenue $1.74M (+5.4% YoY); gross margin fell to 19.0% from 29.8% on higher costs.
- Net loss $7.9M ($0.22/share) vs $5.1M ($0.24) YoY; operating expenses up 48% to $8.6M.
- CGuard stent sales 2,969 units; one-year C-GUARDIANS trial primary endpoint rate 1.95% (lowest ever).
- Raised $17.9M gross from full exercise of Series H warrants; cash & equivalents $47.2M at June 30.
- Intends to submit PMA application to FDA this quarter; plans CGUARDIANS II TCAR trial in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/0001493152-24-030372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315224030372/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer